Skip to main content
. 2021 May 26;9:689613. doi: 10.3389/fcell.2021.689613

FIGURE 2.

FIGURE 2

SB225002 suppresses tumorigenesis in NPC cells in vitro and in vivo. (A) SB225002 inhibited cell proliferation. C666-1 and HONE-1 human NPC cells were treated with SB225002 for (24, 48, and 72 h), cell viability was evaluated by CCK8 assay (**p < 0.01; ***p < 0.001; Student’s t-test). Values represent mean ± SD (n = 5). (B) The effects of SB225002 on colony formation in C666-1 and HONE-1 cells for 10-12 days. The colonies were counted and shown with histograms (**p < 0.01; ***p < 0.001; Student’s t-test). Values represent mean ± SD (n = 3). (C) Cell cycle analysis of C666-1 and HONE-1 cells after SB225002 treatment for 8 h (**p < 0.01; ***p < 0.001; Student’s t-test). Values represent mean ± SD (n = 3). (D) The expression of p38, p-p38, ERK, p-ERK, JNK and p-JNK in C666-1 and HONE-1 cells pre-treated with SB225002 for 2 h determined by western blot analyses and β-actin was employed as a standard. (E–G) C666-1 cells were established subcutaneous in female BALB/c mice and SB225002 at 10 mg/kg and vehicle administration once daily were started 5 days after inoculation. Tumor volumes and tumor weights were recorded every three days (seven mice per group). (E) Representative images of the xenograft tumors in three groups. (F) The growth curves of the tumors in groups were presented. Data are shown as the mean tumor volume ± SD (n = 7; **p < 0.01; two-way ANOVA). (G) The antitumor effects of SB225002 on the tumor weight in groups were shown as mean ± SD (n = 7; **p < 0.01; Student’s t-test).